- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00967577
177Lu-J591 Antibody in Patients With Nonprostate Metastatic Solid Tumors
177Lu Radiolabeled Monoclonal Antibody HuJ591-GS (177Lu-J591) in Patients With Nonprostate Metastatic Solid Tumors: A Pilot Study
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
177Lu-J591 is made up of two compounds called J591 and 177Lutetium (177Lu) that are joined together by a connecting molecule called "DOTA". J591 is a monoclonal antibody, or a type of protein. 177Lu is a radioactive molecule that is being tested for the possible treatment of cancer when joined to monoclonal antibodies. J591 attaches to a protein called prostate specific membrane antigen (PSMA) found in the body. PSMA is mostly found in normal and cancerous prostate cells. In addition, however, PSMA has also been found on the vasculature (blood vessels) that supply multiple types of cancer including colorectal, kidney, bladder, head and neck, breast, non-small cell lung, pancreas, ovary, esophagus and gliomas.
We hope that 177Lu-J591 will seek out blood vessels that supply these tumors and deliver a dose of radiation (from the 177Lu molecule) to the areas of cancer, without affecting target blood vessel that are not associated with the cancer.
Zirconium-89 (89Zr) is a radioactive tracer that allows special scans to be performed prior to administration of the study drug to determine where the antibody goes in the body and to screen the tumor's blood vessels to see if they attract J591. Again, DOTA is used to join the radioactive material to J591. 89Zr-J591 is not being given to treat cancer.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
New York
-
New York, New York, United States, 10021
- Weill Cornell Medical College
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Histologically, or cytologically documented, advanced stage, malignant adult solid tumors (except prostate cancer) that are refractory to, or recurrent from, standard therapy or for which no curative standard therapy exists. This will include, but is not limited to patients with cancers of the kidney, urothelium, head and neck, breast, non-small cell lung, colorectal, pancreas, ovary, esophagus and gliomas.
- Metastatic or recurrent solid tumor malignancy defined by abnormal CT, MRI, PET scan, CXR and/or bone scan
- Progressive disease manifest by: Development of new lesions or an increase in size of preexisting lesions on imaging study or by physical examination.
- Subjects must have recovered from the acute toxicities of any prior therapy, and not received chemotherapy, radiation therapy or other investigational anticancer therapeutic drug for at least 4 weeks prior to J591 administration in this trial
- All subjects must have archived or current tissue (from a primary or metastatic focus) available for PSMA determination.
- Subjects on bisphosphonate therapy or denosumab must be on a stable dose and must have started therapy > 4 weeks prior to protocol therapy.
- Subjects will be informed as to the potential risk of procreation while participating on this trial and will be advised to use effective contraception during the entire study period. Females of child-bearing potential must have a negative pregnancy test.
Exclusion Criteria:
- Use of platelet transfusions within 4 weeks of treatment.
- Use of hematopoietic growth factors within 4 weeks of treatment.
- Prior cytotoxic chemotherapy and/or radiation therapy within 4 weeks of treatment.
- Prior radiation therapy encompassing >25% of skeleton.
- Prior treatment with 89Strontium or 153Samarium containing compounds (e.g. Metastron®, Quadramet®)
- Platelet count <150,000/mm3 or history of platelet count abnormality or dysfunction.
- Absolute neutrophil count (ANC) <2,000/mm3
- Hematocrit <30 percent or Hemoglobin < 10 g/dL
- Abnormal coagulation profile (PT or INR, PTT) > 1.3x upper limit of normal (ULN) unless on therapeutic anticoagulation
- Serum creatinine > 2x ULN
- AST (SGOT) >2.5x ULN
- Bilirubin (total) >1.5x ULN; subjects with known Gilbert's syndrome are eligible if direct bilirubin is within institutional normal limits
- Active serious infection
- Active angina pectoris or NY Heart Association Class III-IV
- ECOG Performance Status > 2
- Deep vein thrombosis and/or pulmonary embolus within 1 month of enrollment.
- Other serious illness(es) involving the cardiac, respiratory, CNS, renal, hepatic or hematological organ systems which might preclude completion of this study or interfere with determination of causality of any adverse effects experienced in this study.
- Prior investigational therapy (medications or devices) within 4 weeks of treatment.
- Known history of HIV.
- Known leukemia or myelodysplastic syndrome
- Prior allergic reaction to Gadolinium contrast.
- Life expectancy < 3 months
- If alternative treatments are available, metastatic disease should not be progressing so as to anticipate the necessity of urgent treatment within 12 weeks of enrollment based on clinical assessment of the investigator
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: J591
|
70 mCi/m2 of 177Lu-J591 will be administered on Day 1.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Change in tumor perfusion as based on Dynamic Contrast Enhanced (DCE)-MRI study
Time Frame: Performed after administration of 177LuJ591 between Day 6-9 and on Day 29.
|
Performed after administration of 177LuJ591 between Day 6-9 and on Day 29.
|
Change in tumor perfusion based on changes in cellularity as assessed using Diffusion-weighted imaging (DWI)
Time Frame: Performed after administration of 177LuJ591 between Day 6-9 and on Day 29.
|
Performed after administration of 177LuJ591 between Day 6-9 and on Day 29.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Changes in response rate using Response evaluation criteria in solid tumors (RECIST) Criteria
Time Frame: Objective response will be evaluated from changes in baseline to Day 99 and repeated every 3 months until radiographic progression of disease.
|
Through RECIST criteria, objective response will be evaluated by taking into account the measurement of the longest diameter only for all target lesions on CT scans as well as normalization of serum tumor markers (if applicable).
|
Objective response will be evaluated from changes in baseline to Day 99 and repeated every 3 months until radiographic progression of disease.
|
Change in the number of subjects who achieve Progression Free Survival
Time Frame: Day 58 after administration with 177Lu-J591 and repeated every 3 months until radiographic progression of disease
|
Progression free survival is the length of time during and after the treatment of a disease, such as cancer, that a patient lives with the disease but it does not get worse.
This will be calculated from the time of treatment (day of 177Lu-J591 infusion) until radiographic progression or death.
|
Day 58 after administration with 177Lu-J591 and repeated every 3 months until radiographic progression of disease
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 0902010212
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Kidney Cancer
-
Case Comprehensive Cancer CenterNational Cancer Institute (NCI)WithdrawnKidney/Urinary Cancer
-
PfizerCompletedKidney Cancer | Kidney Neoplasms | Renal Cell Carcinoma | Renal Cancer | Renal Cell Cancer | Cancer of the Kidney | Cancer of KidneyFinland
-
Tianjin Medical University Second HospitalRecruiting
-
Tianjin Medical University Second HospitalRecruiting
-
Cedars-Sinai Medical CenterRecruitingProstate Cancer Stage II | Prostate Cancer Stage I | Bladder Cancer Stage II | Kidney Cancer Stage IUnited States
-
Dana-Farber Cancer InstituteCompletedKidney Cancer | Prostate Cancer | Genitourinary CancerUnited States
-
Intuitive SurgicalCompleted
-
University of Texas Southwestern Medical CenterCompletedKidney Cancer | Kidney Cancer Metastatic | Kidney Cancer, Stage IVUnited States
-
Yale UniversityCompleted
-
Stanford UniversityNational Cancer Institute (NCI)WithdrawnProstate Cancer | Bladder Cancer | Kidney Tumor
Clinical Trials on 177Lu-J591
-
Weill Medical College of Cornell UniversityCompletedProstate CancerUnited States
-
Weill Medical College of Cornell UniversityTerminated
-
Weill Medical College of Cornell UniversityPOINT BiopharmaSuspendedProstate CancerUnited States
-
Weill Medical College of Cornell UniversityCompleted
-
Weill Medical College of Cornell UniversityUnited States Department of DefenseActive, not recruitingProstate CancerUnited States
-
Weill Medical College of Cornell UniversityCompleted
-
IpsenTerminatedGastric Cancer | Colorectal Cancer | Bone Cancer | Squamous Cell Carcinoma of the Head and Neck | Advanced Cancer | Recurrent Disease | Pancreatic Ductal Adenocarcinoma | Metastatic TumoursUnited States, France, Belgium, Switzerland, Netherlands
-
The First Affiliated Hospital of Xiamen UniversityRecruiting
-
Sidney Kimmel Comprehensive Cancer Center at Johns...Adenoid Cystic Carcinoma Research Foundation; Progenics Pharmaceuticals, Inc.Not yet recruitingAdenoid Cystic CarcinomaUnited States
-
Telix International Pty LtdNot yet recruiting